# The Role of Levosimendan as Inotropic Agent in Acute Aluminum Phosphide-induced Cardiotoxicity

> **NCT06478667** · PHASE3 · COMPLETED · sponsor: **Ain Shams University** · enrollment: 50 (actual)

## Conditions studied

- Acute Myocarditis

## Interventions

- **DRUG:** levosemindan

## Key facts

- **NCT ID:** NCT06478667
- **Lead sponsor:** Ain Shams University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-12-20
- **Primary completion:** 2025-01-20
- **Final completion:** 2025-01-20
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2025-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06478667

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06478667, "The Role of Levosimendan as Inotropic Agent in Acute Aluminum Phosphide-induced Cardiotoxicity". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06478667. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*